Foundation Medicine Launches ICE 2, Its New Version of Interactive Cancer Explorer, Featuring PatientMatch
ICE 2 Enables Physicians To More Effectively Leverage Comprehensive Genomic Profiling In Their Practices
"By releasing ICE 2,
First launched in 2012, Foundation Medicine's online portal gives physicians access to test reports from FoundationOne and FoundationOne Heme on their tablet, computer or mobile device. ICE 2 offers several new features that increase the efficiency of patient care, including sample tracking, notifications and enhanced search, which allows physicians to find patients by gene, alteration or tumor type. In addition, ICE 2 features a brand new service called PatientMatch that identifies and connects physicians across Foundation Medicine's network who have seen patients with similar genomic profiles and tumor types, allowing them to share clinical experiences and outcomes data to help inform treatment decisions.
To learn more about ICE 2, please visit http://foundationone.com/learn.php#4.
About FoundationOne®
FoundationOne, the company's first clinical product, is a fully informative genomic profile for solid tumors used by oncologists to identify the molecular alterations in a patient's tumor and match those alterations with relevant targeted therapies and clinical trials. Using next-generation sequencing in routine cancer specimens, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations including base substitutions, insertions, deletions, copy number alterations and select rearrangements. FoundationOne fits easily into the clinical workflow of the ordering physician, and test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. FoundationOne is a laboratory-developed test performed at Foundation Medicine's CLIA-certified lab. The test is accredited by CAP, is approved by the New York State Department of Health and has received a CE Mark. Please visit www.FoundationOne.com for more information.
About FoundationOne® Heme
FoundationOne Heme is a fully informative genomic profile for hematologic cancers (leukemia, lymphoma and myeloma) and sarcomas, designed to provide physicians with clinically actionable information to guide treatment options for patients based on the genomic profile of their cancer. It is
About
Cautionary Note Regarding Forward-Looking Statements for
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the launch of a new version of Interactive Cancer Explorer, the ability of ICE 2 assist physicians in providing care to cancer patients using Foundation Medicine's comprehensive genomic profiling, and the potential impact of current and future enhancements to patient treatment. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that ICE 2 does not perform as expected; that subsequent enhancements to Interactive Cancer Explorer are not developed; that future versions of Interactive Cancer Explorer do not impact the treatment of cancer; and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2013, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.
Media Contact:
dan@purecommunicationsinc.com
or
Investor Contact:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media